Back to Search
Start Over
[Clinical Efficacy of Crizotinib in Advanced ALK Positive Non-small Cell Lung Cancer].
- Source :
-
Zhongguo fei ai za zhi = Chinese journal of lung cancer [Zhongguo Fei Ai Za Zhi] 2015 Oct 20; Vol. 18 (10), pp. 616-20. - Publication Year :
- 2015
-
Abstract
- Background: The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.<br />Methods: patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14). Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily. Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up.<br />Results: Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026). The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% (χ2=5.600, P=0.018). Median progression free survival (PFS) of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group (4.0 mo)(P=0.002).<br />Conclusions: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced ALK positive non-small cell lung cancer. The median PFS of patients is shorter. It can improve the quality of life about patients. .
- Subjects :
- Adult
Anaplastic Lymphoma Kinase
Antineoplastic Agents adverse effects
Carcinoma, Non-Small-Cell Lung enzymology
Carcinoma, Non-Small-Cell Lung genetics
Crizotinib
Female
Humans
Lung Neoplasms enzymology
Lung Neoplasms genetics
Male
Middle Aged
Protein Kinase Inhibitors adverse effects
Pyrazoles adverse effects
Pyridines adverse effects
Quality of Life
Receptor Protein-Tyrosine Kinases antagonists & inhibitors
Receptor Protein-Tyrosine Kinases genetics
Treatment Outcome
Young Adult
Antineoplastic Agents administration & dosage
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Protein Kinase Inhibitors administration & dosage
Pyrazoles administration & dosage
Pyridines administration & dosage
Receptor Protein-Tyrosine Kinases metabolism
Subjects
Details
- Language :
- Chinese
- ISSN :
- 1999-6187
- Volume :
- 18
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Zhongguo fei ai za zhi = Chinese journal of lung cancer
- Publication Type :
- Academic Journal
- Accession number :
- 26483333
- Full Text :
- https://doi.org/10.3779/j.issn.1009-3419.2015.10.03